Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user recovered from Post-Finasteride Syndrome (PFS) using a specific hormone protocol after trying finasteride and dutasteride. They now help others with PFS by reviewing blood work and offering personalized advice.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

The user experienced hair improvement over a year using finasteride, topical minoxidil, tretinoin, ketoconazole, and microneedling. The hair density and hairline have strengthened with this routine.

The user started oral finasteride in October 2025, switched to topical finasteride and minoxidil in mid-2026, and uses a dermastamp weekly. They are unsure about regrowth progress and feel insecure about their hairline.

The user is happy with hair growth progress after using minoxidil foam and 1mg finasteride for over six months, despite initial scalp itching. They are considering switching to oral minoxidil for faster growth and are concerned about maintaining consistency with the foam application.

A new topical finasteride has been approved in France, providing an alternative to oral finasteride with potentially fewer side effects. Users discuss the pros and cons of topical versus oral treatments, with some opting to create their own solutions to save money.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

The user experienced significant hair improvement using 1mg finasteride and 2.5mg oral minoxidil daily, with most gains attributed to finasteride. They also stopped using topical treatments due to scalp psoriasis and reported no major side effects.

The user shared their one-year progress using 5% topical minoxidil and 1mg oral finasteride, reporting good results with some shedding phases. They experienced no side effects and noted improved hair density, especially in the frontal area.

France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.

A 33-year-old experienced significant hair regrowth on the crown after one year of using oral finasteride (1mg) and minoxidil (2.5mg) daily, with initial concerns about libido that resolved after a week. The user reported minimal shedding and no other side effects, making a hair transplant optional.

The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.

Hair regrowth and gender transition using finasteride, estrogen, and spironolactone. Significant hair regrowth and personal transformation were achieved through hormone replacement therapy.

User shared a 2-year progress update on hair regrowth using 1mg finasteride and 2.5mg oral minoxidil daily. They switched from topical to oral minoxidil for ease of use and showed significant improvement.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The user shared their one-year hair growth progress using a daily Fin/Min chewable tablet, noting some inconsistency in usage but still achieving results. They use Head & Shoulders shampoo and have not mentioned any side effects.

The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.

Amplifica is developing new molecules for hair growth, with clinical trials expected soon, while Engraft Technologies is improving FUE robotic technology to make hair transplants faster and cheaper. Users express interest in the timeline for AMP-303 and concerns about high costs and effectiveness of current treatments.

The conversation discusses the impact of finasteride on sperm, including potential side effects like decreased ejaculate volume and total sperm count. Users share experiences and concerns about fertility tests before and after starting finasteride.

The conversation is about trying DS Labs SOD supplements for hair loss, which contain ingredients like Genistein, B-sitosterol, and Biotin. The user is considering adding these supplements to their existing hair care routine.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Topical finasteride in a liposomal formulation reduces systemic absorption compared to ethanol solutions. The user is seeking sources for such products, noting that popular options like morr-f are not liposomal.

The user started taking Finasteride 1mg daily on June 24, 2024, with no negative side effects and shares weekly progress pictures. They use coconut oil for deep conditioning weekly.

A humorous discussion about hair regrowth using finasteride, with jokes about telekinesis and tiny ants. The conversation is satirical, with users making light of hair loss treatments.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Finasteride may affect prostate sensation and size, with some users reporting easier urination. Concerns exist about prostate shrinkage even at lower doses.

The user shared progress pictures after one year on finasteride, suggesting it was effective for hair loss. The conversation includes humorous and sarcastic comments about the results and side effects.

PP405 and JXL069 are confirmed to be the same molecule, leading to disappointment due to poor hair regrowth results. Users express skepticism about the credibility of Pelage and the effectiveness of JXL069.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.